NCT05946122 is a Phase 1 clinical trial of Atorvastatin 40 Mg Oral Tablet in Renal Protection, sponsored by Minia University.

Who is sponsoring NCT05946122?

NCT05946122 is sponsored by Minia University.

What drugs are being tested in NCT05946122?

Interventions in NCT05946122: Atorvastatin 40 Mg Oral Tablet, placebo drug.

What condition does NCT05946122 study?

NCT05946122 studies Renal Protection.

Is NCT05946122 still recruiting?

NCT05946122 is currently status unknown. Last updated 14 July 2023.

Last reviewed 2023-07-14 · How we verify

NCT05946122

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Atorvastatin as a Renal Protection in Patients With Systemic Inflammatory Response Syndrome Using Renal Arterial Resistive Index

Status unknown Phase 1 Last updated 14 July 2023

What this trial tests

Phase 1 trial testing Atorvastatin 40 Mg Oral Tablet in Renal Protection in 106 participants. Status unknown.

Timeline

30 May 2023

Primary endpoint
12 December 2023

30 December 2023

Quick facts

Lead sponsor	Minia University
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	106
Start date	30 May 2023
Primary completion	12 December 2023
Estimated completion	30 December 2023
Sites	1 location across Egypt

Drugs / interventions tested

Atorvastatin 40 Mg Oral Tablet
placebo drug — full drug profile →

Conditions studied

Renal Protection — all drugs for Renal Protection →

Sponsor

Minia University

Who can join

Adults 25 to 70, any sex, with Renal Protection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Offering renal protection in systemic inflammatory response syndrome by atorvastatin

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effect of atorvastatin as a renal protective agent in patients with systemic inflammatory response syndrome using the renal arterial resistive index.
Raouf MM, Shadad EA, Ali NS. · · 2025 · cited 1× · PMID 39978955 · DOI 10.4266/acc.003912

Verify or expand the search:

Other trials of Atorvastatin 40 Mg Oral Tablet

Trials testing the same drug.

NCT07508254 — Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome · Phase 4 · not yet recruiting
NCT06360120 — Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic Stroke · Phase 3 · recruiting
NCT04789057 — Atorvastatin Effect on Reduction of COPD Exacerbations · Phase 4 · recruiting
NCT05806723 — Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men · Phase 4 · completed
NCT04262206 — Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults · Phase 4 · recruiting

Other Minia University trials

Trials by the same sponsor.

NCT07525687 — Temporary Uterine Tourniquet Application Versus Local Myometrial Epinephrine Injection During Laparoscopic Myomectomy · NA · not yet recruiting
NCT07525674 — Vacuum Sealing Drainage (VSD) in Promoting Wound Healing and Reducing Complications in Post-Infected Obstetric and Gynec · NA · not yet recruiting
NCT07529587 — Laparoscopic Umbilico-uterine Trunk Clipping Approach in the Management of Enhanced Myometrial Vascularity · NA · not yet recruiting
NCT07500558 — Ultrasound Guided Infratemporal Sphenopalatine Ganglion Supravoltage Versus Standard Voltage Pulsed Radiofrequency for P · NA · not yet recruiting
NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05946122 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Minia University
Last refreshed: 14 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05946122.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing